M.D. Anderson Cancer Center
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
Primary Objectives: * To determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of eribulin in combination with fixed doses of irinotecan and temozolomide. * To determine the safety and tolerance of Eribulin when given in conjunction with Irinotecan and Temozolamide (IT) in children with refractory and relapsed (R/R) solid tumors. Secondary Objectives: --To observe and record disease response (anti-tumor activity). Although the clinical benefit of Eribulin when given together with Irinotecan and Temozolamide has not yet been established, the intent of offering this trea…
Inclusion Criteria: * Age: Patients must be \> 1 year of age and ≤ 25 years of age at time of initiation of protocol therapy. * Diagnosis: Patients have a histologically or radiographically confirmed relapsed or refractory solid tumor. * Disease Status: Patients must have evaluable disease. * Patients may have CNS metastases at study entry, if they are previously treated or stable (defined by not requiring initation or increased steroids for 7 days). * Performance Level: Karnofsky ≥ 50% for patients \>16 years old, and Lansky ≥ 50 for patients 1-16 years old. (Appendix I) * Prior Therapy: Pat…
Given by vein (IV)
Given by vein (IV)
Given by PO
Arctuva estimate
Verify or correct the compensation shown for this listing.